Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May-Jun;8(4):401-405.
Epub 2017 May 1.

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma

Krista G Ramirez  1
Affiliations
Review

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma

Krista G Ramirez. J Adv Pract Oncol. 2017 May-Jun.

Abstract

The FDA approval of ixazomib for use in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy signalled the arrival of the first oral proteasome inhibitor, allowing advanced practitioners to provide multiple myeloma patients an exclusively oral triplet therapy.

PubMed Disclaimer

Figures

Table 1
Table 1
Ixazomib Dosing Schedule
Table 2
Table 2
Ixazomib Dose Modification in Hepatic and Renal Impairment
Table 3
Table 3
INFORTable 3. Dose Reductions for Hematologic and Nonhematologic Toxicities
See this image and copyright information in PMC

References

    1. Dou Q Ping, Zonder Jeffrey A. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Current cancer drug targets. 2014;14:517–536. - PMC - PubMed
    1. Durie B, Hoering A, Rajkumar S V, Abidi M H, Epstein J, Kahanic S P, Dispenzieri A. Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): Results of the randomized phase III trial SWOG S0777 [Abstract] Blood (ASH Annual Meeting Abstracts) 2015;126(23):25. Retrieved from http://www.bloodjournal.org/content/126/23/25 .
    1. Millennium Pharmaceuticals, Inc. Ninlaro (ixazomib) package insert. 2015b Retrieved from https://www.ninlaro.com/prescribing-information.pdf.
    1. Millennium Pharmaceuticals, Inc. Velcade (bortezomib) package insert. 2015a Retrieved from http://www.velcade.com/files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf .
    1. Moreau Philippe, Masszi Tamás, Grzasko Norbert, Bahlis Nizar J, Hansson Markus, Pour Ludek, Sandhu Irwindeep, Ganly Peter, Baker Bartrum W, Jackson Sharon R, Stoppa Anne-Marie, Simpson David R, Gimsing Peter, Palumbo Antonio, Garderet Laurent, Cavo Michele, Kumar Shaji, Touzeau Cyrille, Buadi Francis K, Laubach Jacob P, Berg Deborah T, Lin Jianchang, Di Bacco Alessandra, Hui Ai-Min, van de Velde Helgi, Richardson Paul G. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. The New England journal of medicine. 2016;374:1621–1634. - PubMed

LinkOut - more resources